<PAGE>
RULE NO. 424(b)(1)
REGISTRATION NO. 333-89355
PROSPECTUS
[LOGO OF BIOTECH HOLDERs](SM)
1,000,000,000 Depositary Receipts
Biotech HOLDRs(SM) Trust
The Biotech HOLDRsSM Trust will issue Depositary Receipts called Biotech
HOLDRs(SM) representing your undivided beneficial ownership in the common stock
of a group of 20 specified companies that are involved in various segments of
the biotechnology industry. The Bank of New York will be the trustee. You only
may acquire, hold or transfer Biotech HOLDRs in a round-lot amount of 100
Biotech HOLDRs or round-lot multiples. Biotech HOLDRs are separate from the
underlying deposited common stocks that are represented by the Biotech HOLDRs.
For a list of the names and the number of shares of the companies that make up
a Biotech HOLDRs, see "Highlights of Biotech HOLDRs--The Biotech HOLDRs"
starting on page 8. Merrill Lynch, Pierce, Fenner & Smith Incorporated has
sold 4,500,000 Biotech HOLDRs in the initial distribution. The trust will
issue the additional Biotech HOLDRs on a continuous basis after the initial
distribution.
Investing in Biotech HOLDRs involves significant risks. See "Risk
factors" starting on page 4.
The initial public offering price for a round-lot of 100 Biotech HOLDRs
equals the sum of the closing market price on November 22, 1999 for each
deposited share multiplied by the share amount specified in this prospectus,
plus an underwriting fee.
Biotech HOLDRs are neither interests in nor obligations of either the
initial depositor, Merrill Lynch, Pierce, Fenner & Smith Incorporated, or The
Bank of New York, as trustee.
Prior to this issuance, there has been no public market for Biotech
HOLDRs. The Biotech HOLDRs have been approved for listing on the American
Stock Exchange under the symbol "BBH," subject to official notice of issuance.
----------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
<TABLE>
<CAPTION>
Initial
Price to Underwriting
Public* Fee
-------- ------------
<S> <C> <C>
Per Biotech HOLDR.................................... $109.18 2%
</TABLE>
--------
* Includes underwriting fee.
For purchases of Biotech HOLDRs in excess of 10,000 Biotech HOLDRs, the
underwriting fee will be 1%.
----------------
Merrill Lynch & Co.
----------------
The date of this prospectus is November 22, 1999.
"HOLDRs" and "HOLding Company Depositary Receipts" are service marks of
Merrill Lynch & Co., Inc.
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
Summary.................................................................... 3
Risk factors............................................................... 4
Highlights of Biotech HOLDRs............................................... 8
The trust.................................................................. 14
Description of Biotech HOLDRs.............................................. 14
Description of the underlying securities................................... 15
Description of the depositary trust agreement.............................. 17
Federal income tax consequences............................................ 20
ERISA considerations....................................................... 21
Plan of distribution....................................................... 21
Year 2000.................................................................. 22
Legal matters.............................................................. 23
Where you can find more information........................................ 23
</TABLE>
----------------
This prospectus contains information you should consider when making your
investment decision. With respect to information about Biotech HOLDRs, you
should rely only on the information contained in this prospectus. We have not
authorized any other person to provide you with different information. If
anyone provides you with different or inconsistent information, you should not
rely on it. We are not making an offer to sell Biotech HOLDRs in any
jurisdiction where the offer or sale is not permitted.
2
<PAGE>
SUMMARY
The Biotech HOLDRs trust will be formed under the depositary trust
agreement, dated as of November 18, 1999 among The Bank of New York, as
trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors
and the owners of the Biotech HOLDRs. The trust is not a registered investment
company under the Investment Company Act of 1940.
The trust will hold shares of common stock issued by 20 specified
companies generally considered to be involved in various segments of the
biotechnology industry. The number of shares of each common stock held by the
trust with respect to each round-lot of Biotech HOLDRs is specified under
"Highlights of Biotech HOLDRs--The Biotech HOLDRs." This group of common
stocks is referred to as the underlying securities. Except when a
reconstitution event occurs, the underlying securities will not change.
Under no circumstances will a new company be added to the group of
issuers of underlying securities.
The trust will issue Biotech HOLDRs that represent your undivided
beneficial ownership interest in the shares of common stock held by the trust
on your behalf. The Biotech HOLDRs are separate from the underlying common
stocks that are represented by the Biotech HOLDRs.
3
<PAGE>
RISK FACTORS
An investment in Biotech HOLDRs involves risks similar to investing in
each of the underlying securities outside of the Biotech HOLDRs, including the
risks associated with concentrated investments in the biotechnology industry.
General Risk Factors
. Loss of investment. Because the value of Biotech HOLDRs directly
relates to the value of the underlying securities, you may lose
all or a substantial portion of your investment in the Biotech
HOLDRs if the underlying securities decline in value.
. Discount trading price. Biotech HOLDRs may trade at a discount to
the aggregate value of the underlying securities.
. Not necessarily representative of the biotechnology
industry. While the underlying securities are common stocks of
companies generally considered to be involved in various segments
of the biotechnology industry, the underlying securities and the
Biotech HOLDRs may not necessarily follow the price movements of
the entire biotechnology industry generally. If the underlying
securities decline in value, your investment in the Biotech HOLDRs
will decline in value even if common stock prices in the
biotechnology industry generally increase in value. Furthermore,
after the initial deposit, one or more of the issuers of the
underlying securities may no longer be involved in the
biotechnology industry. In this case, the Biotech HOLDRs may no
longer consist of securities issued only by companies involved in
the biotechnology industry.
. No investigation of underlying securities. The underlying
securities included in the Biotech HOLDRs were selected by Merrill
Lynch, Pierce, Fenner & Smith Incorporated based on the market
capitalization of issuers and the market liquidity of common
stocks in the biotechnology industry, without regard for the
value, price performance, volatility or investment merit of the
underlying securities. The Biotech HOLDRs trust, the trustee,
Merrill Lynch, Pierce, Fenner & Smith Incorporated, and their
affiliates, have not performed any investigation or review of the
selected companies, including the public filings by the companies.
Investors and market participants should not conclude that the
inclusion of a company is any form of investment recommendation by
the trust, the trustee, Merrill Lynch, Pierce, Fenner & Smith
Incorporated, or their affiliates.
. Loss of diversification. As a result of business developments,
reorganizations, or market fluctuations affecting issuers of the
underlying securities, Biotech HOLDRs may not necessarily continue
to be a diversified investment in the biotechnology industry. As a
result of market fluctuation and/or reconstitution events, Biotech
HOLDRs may represent a concentrated investment in one or more of
the underlying securities which would reduce investment
diversification and increase your exposure to the risks of
concentrated investments.
. Conflicting investment choices. In order to sell one or more of
the underlying securities individually or to participate in a
tender offer relating to one or more of the underlying securities,
you will be required to cancel your Biotech HOLDRs and receive
delivery of each of the underlying securities. The cancellation of
your Biotech HOLDRs will allow you to sell individual underlying
securities or to deliver individual underlying securities in a
tender offer. The cancellation of Biotech HOLDRs will involve
payment of a cancellation fee to the trustee.
. Trading halts. Trading in Biotech HOLDRs may be halted in the
event trading in one or more of the underlying securities is
halted. If so, you will not be able to trade Biotech
4
<PAGE>
HOLDRs even though there is trading in some of the underlying
securities; however, you will be able to cancel your Biotech
HOLDRs to receive the underlying securities.
. Delisting from the American Stock Exchange. If the number of
companies whose common stock is held in the trust falls below
nine, the American Stock Exchange may consider delisting the
Biotech HOLDRs. If the Biotech HOLDRs are delisted by the American
Stock Exchange, a termination event will result if the Biotech
HOLDRs are not listed for trading on another national securities
exchange or through NASDAQ within five business days from the date
the Biotech HOLDRs are delisted.
. Possible conflicts of interest. Merrill Lynch, Pierce, Fenner &
Smith Incorporated, as initial depositor, has selected the
underlying securities and may face possible conflicts of interest
in connection with its activities. For example, Merrill Lynch,
Pierce, Fenner & Smith Incorporated and its affiliates,
collectively referred to as Merrill Lynch, may engage in
investment banking and other activities, may provide services to
issuers of the underlying securities in connection with its
business, or may trade in the underlying securities for its own
account. All of these activities may result in conflicts of
interest with respect to the financial interest of Merrill Lynch,
on the one hand, and, on the other hand, the initial selection of
the underlying securities included in the Biotech HOLDRs, the
selection of the biotechnology industry, Merrill Lynch's activity
in the secondary market in the underlying securities, and the
creation and cancellation of Biotech HOLDRs by Merrill Lynch.
. Temporary price increases in the underlying securities. Purchasing
activity in the secondary trading market associated with acquiring
the underlying securities for deposit into the trust may affect
the market price of the deposited shares. Large volumes of
purchasing activity, which may occur in connection with the
issuance of Biotech HOLDRs, particularly in connection with the
initial issuance of Biotech HOLDRs, could temporarily increase the
market price of the underlying securities, resulting in a higher
price on that date. This purchasing activity could create a
temporary imbalance between the supply and demand of the
underlying securities, thereby limiting the liquidity of the
underlying securities due to a temporary increased demand for
underlying securities. Consequently, prices for the underlying
securities may decline after these purchases as the volume of
purchases subsides. This in turn is likely to have an immediate,
adverse effect on the trading price of Biotech HOLDRs.
Risk Factors Specific to the Biotechnology Industry
. Biotechnology company stock prices have been and will likely
continue to be extremely volatile. The trading prices of the
stocks of biotechnology companies have been and are likely to be
extremely volatile. Biotechnology companies' stock prices could be
subject to wide fluctuations in response to a variety of factors,
including:
. announcements of technological innovations or new commercial
products;
. developments in patent or proprietary rights;
. government regulatory initiatives;
. public concern as to the safety or other implications of
biotechnology products;
. fluctuations in quarterly financial results; and
. market conditions.
. Biotechnology companies face uncertainty with respect to pricing
and third party reimbursement. Biotechnology companies will
continue to be affected by the efforts of governments and third
party payors, such as government health organizations, private
health
5
<PAGE>
insurers and health maintenance organizations, to contain or
reduce health care costs. For example, in certain foreign markets
pricing or profitability of biotechnology products and
technologies is subject to control. In the United States, there
has been, and there will likely to continue to be, a number of
federal and state proposals to implement similar government
control. Also, an increasing emphasis on managed health care in
the United States will continue to put pressure on the pricing of
the products and technologies of biotechnology companies. The
announcement or adoption of such proposals could have a material
adverse affect on a biotechnology companies' business and
financial condition. Further, the sales of the products of many
biotechnology companies are often dependent, in part, on the
availability of reimbursement from third party payors. Third party
payors are increasingly challenging the prices charged for health
care products and technologies and denying or limiting coverage
for new products. Even if a biotechnology company can bring a
product or technology to market, there can be no assurance that
these products or technologies will be considered cost-effective
by third party payors and that sufficient reimbursement will be
available to consumers to allow for the sale of the products and
services on a profitable basis.
. Protection of patent and proprietary rights of biotechnology
companies is difficult and costly. The success of many
biotechnology companies is highly dependent on a biotechnology
company's ability to obtain patents on current and future products
and technologies, to defend its existing patents and trade secrets
and operate in a manner that does not infringe on the proprietary
rights of other biotechnology companies. Patent disputes are
frequent and can preclude the successful commercial introduction
of products and technologies. As a result, there is significant
litigation in the biotechnology industry regarding patent and
other intellectual property rights. Litigation is costly and could
subject a biotechnology company to significant liabilities to
third parties. In addition, a biotechnology company could be
forced to obtain costly third-party licenses or cease using the
technology or product in dispute.
. Biotechnology companies are subject to extensive government
regulation. Products and technologies offered by biotechnology
companies are subject to strict regulation by the Food and Drug
Administration in the United States and similar agencies in other
countries. Many of the products will require extensive pre-
clinical testing, clinical trials, other testing, government
review and final approval before any marketing of the product will
be permitted. This procedure could take a number of years and
involves the expenditure of substantial resources. The success of
a biotechnology company's current or future product will depend,
in part, upon obtaining and maintaining regulatory approval to
market products and, once approved, complying with the continued
review by regulatory agencies. The failure to obtain necessary
government approvals, the restriction of existing approvals, loss
of or changes to previously obtained approvals or the failure to
comply with regulatory requirements could result in fines,
unanticipated expenditures, product delays, non-approval or
recall, interruption of production and even criminal prosecution.
. Biotechnology companies must keep pace with rapid technological
change to remain competitive. The biotechnology industry is highly
competitive and is subject to rapid and significant technological
change. Biotechnology companies will face continued competition as
new products enter the market and advanced technologies become
available. The success of a biotechnology company will depend on
its ability to develop products and technologies that are at least
as clinically effective or cost-effective than its competitors'
products and technologies or that would render its competitors'
products and technologies obsolete or uncompetitive.
. Results of research and development of new products and
technologies are unpredictable. Successful product or technology
development in the biotechnology industry is very uncertain and
only a small number of research and development programs will
result in the
6
<PAGE>
marketing and sale of a new product or technology. Many products
and technologies that appear promising may fail to reach the
market for many reasons, including results indicating lack of
effectiveness or harmful side effects in clinical or pre-clinical
testing, failure to receive necessary regulatory approvals,
uneconomical manufacturing costs or competing proprietary rights.
In addition, there is no certainty that any product or technology
in development will achieve market acceptance from the medical
community, third party payors or individual users.
. Biotechnology companies may be exposed to extensive product
liability costs. The testing, manufacturing, marketing and sale of
many of the products and technologies developed by biotechnology
companies inherently expose biotechnology companies to potential
product liability risks. Many biotechnology companies obtain
limited product liability insurance; further, there can be no
assurance that a biotechnology company will be able to maintain
its product liability insurance, that it will continue to be able
to obtain adequate product liability insurance on reasonable terms
or that any product liability insurance obtained will provide
adequate coverage against potential liabilities.
. Biotechnology companies face challenges gaining governmental and
consumer acceptance of genetically altered products. Biotechnology
companies may be involved in the development of genetically
engineered agricultural and food products. The commercial success
of these products will depend, in part, on governmental and public
acceptance of their cultivation, distribution and consumption.
Public attitudes may be influenced by the media and by opponents
who claim that genetically engineered products are unsafe for
consumption, pose unknown health risks, risks to the environment
or to social or economic practices. Biotechnology companies may
continue to have to expend significant resources to foster
governmental and consumer acceptance of genetically engineered
agricultural and food products, particularly in Europe where
securing governmental approvals for, and achieving consumer
confidence in, these products continues to pose numerous
challenges. The success of any genetically engineered agricultural
and food products may be delayed or impaired in certain
geographical areas due to the existing or future regulatory,
legislative or public acceptance issues. Celera Genomics, one of
the underlying securities of the Biotech HOLDRs, is involved in
the development of genetically-based plant and animal breeding.
Other companies representing underlying securities of the Biotech
HOLDRs may become involved in the development of genetically
engineered agricultural and food products.
. Many biotechnology companies are dependent on key personnel for
success. The success of many biotechnology companies is highly
dependent on the experience, abilities and continued services of
key executive officers and key scientific personnel. If these
companies lose the services of any of these officers or key
scientific personnel, their future success could be undermined.
The success of many biotechnology companies also depends upon
their ability to attract and retain other highly qualified
scientific, managerial sales and manufacturing personnel and their
ability to develop and maintain relationships with qualified
clinical researchers. Competition for such personnel and
relationships is intense and many of these companies compete with
each other and with universities and non-profit research
organizations. There is no certainty that any of these
biotechnology companies will be able to continue to attract and
retain qualified personnel or develop and maintain relationships
with clinical researchers.
7
<PAGE>
HIGHLIGHTS OF BIOTECH HOLDRs
This discussion highlights information regarding Biotech HOLDRs; we
present certain information more fully in the rest of this prospectus. You
should read the entire prospectus carefully before you purchase Biotech HOLDRs.
Issuer....................... Biotech HOLDRs Trust.
The trust.................... The Biotech HOLDRs Trust will be formed under
the depositary trust agreement, dated as of
November 18, 1999 among The Bank of New York,
as trustee, Merrill Lynch, Pierce, Fenner &
Smith Incorporated, other depositors and the
owners of the Biotech HOLDRs. The trust is not
a registered investment company under the
Investment Company Act of 1940.
Initial depositor............ Merrill Lynch, Pierce, Fenner & Smith
Incorporated.
Trustee...................... The Bank of New York, a New York state-
chartered banking organization, will be the
trustee and receive compensation as set forth
in the depositary trust agreement.
Purpose of Biotech HOLDRs....
Biotech HOLDRs are designed to achieve the
following:
Diversification. Biotech HOLDRs are designed to
allow you to diversify your investment in the
biotechnology industry through a single,
exchange-listed instrument representing your
undivided beneficial ownership of the
underlying securities.
Flexibility. The beneficial owners of Biotech
HOLDRs have undivided beneficial ownership
interests in each of the underlying securities
represented by the Biotech HOLDRs, and can
cancel their Biotech HOLDRs to receive each of
the underlying securities represented by the
Biotech HOLDRs.
Transaction costs. The expenses associated with
trading Biotech HOLDRs are expected to be less
than trading each of the underlying securities
separately.
Trust assets................. The trust will hold shares of common stock
issued by 20 specified companies in the
biotechnology industry. Except when a
reconstitution event occurs, the group of
companies will not change. Reconstitution
events are described in this prospectus under
the heading "Description of the depositary
trust agreement-- Reconstitution events." Under
no circumstances will the common stock of a new
company be added to the common stocks
underlying the Biotech HOLDRs.
The trust's assets may increase or decrease as
a result of in-kind deposits and withdrawals of
the underlying securities during the life of
the trust.
The Biotech HOLDRs........... The trust will issue Biotech HOLDRs that
represent your undivided beneficial ownership
interest in the shares of common stock held by
the trust on your behalf. The Biotech HOLDRs
themselves are separate from the underlying
securities that are represented by the Biotech
HOLDRs.
8
<PAGE>
The specific share amounts for each round-lot
of 100 Biotech HOLDRs are set forth in the
chart below and were determined on October 27,
1999 so that the initial weightings of each
underlying security included in the Biotech
HOLDRs approximated the relative market
capitalizations of the specified companies,
subject to a maximum weight of 20%. Because
these weightings are a function of market
prices, it is expected that these weightings
will change substantially over time, including
during the period between October 27, 1999 and
the date the Biotech HOLDRs are first issued to
the public.
The share amounts set forth below will not
change, except for changes due to corporate
events such as stock splits or reverse stock
splits on the underlying securities or
reconstitution events.
The following chart provides the
. names of the 20 issuers of the underlying
securities represented by an Biotech HOLDRs,
. stock ticker symbols,
. share amounts represented by a round-lot of
100 Biotech HOLDRs,
. initial weightings as of October 27, 1999
and
. the principal market on which the shares of
common stock of the selected companies are
traded.
<TABLE>
<CAPTION>
Primary
Name of Share Initial Trading
Company Ticker Amounts Weighting Market
---------------------- ------ ------- --------- -------
<S> <C> <C> <C> <C>
Amgen Inc. AMGN 46 19.76% NASDAQ
Genentech, Inc. DNA 22 18.29% NYSE
Biogen, Inc. BGEN 13 9.92% NASDAQ
Immunex Corporation IMNX 14 8.90% NASDAQ
PE Corp-PE Biosystems
Group PEB 9 6.67% NYSE
MedImmune, Inc. MEDI 5 6.03% NASDAQ
Chiron Corporation CHIR 16 4.78% NASDAQ
Genzyme Corporation GENZ 7 2.99% NASDAQ
Gilead Sciences, Inc. GILD 4 2.97% NASDAQ
Sepracor Inc. SEPR 3 2.68% NASDAQ
IDEC Pharmaceuticals
Corporation IDPH 2 2.49% NASDAQ
QLT Photo Therapeutics
Inc. QLTI 5 2.42% NASDAQ
Millennium
Pharmaceuticals, Inc. MLNM 3 2.35% NASDAQ
BioChem Pharma Inc. BCHE 9 2.20% NASDAQ
Affymetrix, Inc. AFFX 2 2.02% NASDAQ
Human Genome Sciences,
Inc. HGSI 2 1.77% NASDAQ
ICOS Corporation ICOS 4 1.29% NASDAQ
Enzon, Inc. ENZN 3 0.93% NASDAQ
Celera Genomics CRA 2 0.77% NYSE
Alkermes, Inc. ALKS 2 0.76% NASDAQ
</TABLE>
These companies generally are considered to be
among the 20 largest and most liquid companies
involved in the biotechnology industry as
measured by market capitalization and trading
volume on October 27, 1999. The market
capitalization of a company is determined by
multiplying the price of its common stock by
the number of outstanding shares of its common
stock.
9
<PAGE>
The trust only will issue and cancel, and you
only may obtain, hold, trade or surrender,
Biotech HOLDRs in a round-lot of 100 Biotech
HOLDRs and round-lot multiples. The trust will
only issue Biotech HOLDRs upon the deposit of
the whole shares represented by a round-lot of
100 Biotech HOLDRs. In the event that a
fractional share comes to be represented by a
round-lot of Biotech HOLDRs, the trust may
require a minimum of more than one round-lot of
100 Biotech HOLDRs for an issuance so that the
trust will always receive whole share amounts
for issuance of Biotech HOLDRs.
The number of outstanding Biotech HOLDRs will
increase and decrease as a result of in-kind
deposits and withdrawals of the underlying
securities. The trust will stand ready to issue
additional Biotech HOLDRs on a continuous basis
when an investor deposits the required shares
of common stock with the trustee.
Public offering price........ The initial public offering price for 100
Biotech HOLDRs equals the sum of the closing
market price on November 22, 1999 for each
underlying security multiplied by the share
amount appearing in the above table, plus an
underwriting fee.
Purchases.................... After the initial offering, you may acquire
Biotech HOLDRs in two ways:
. through an in-kind deposit of the required
number of shares of common stock of the
underlying issuers with the trustee, or
. through a cash purchase in the secondary
trading market.
Underwriting fees............
If you purchase Biotech HOLDRs in the initial
public offering, you will pay Merrill Lynch,
Pierce, Fenner & Smith Incorporated, in its
role as underwriter, an underwriting fee equal
to:
. For purchases of 10,000 Biotech HOLDRs or
fewer, 2%.
. For purchases in excess of 10,000 Biotech
HOLDRs, 1%.
You will not be charged any issuance fee or
other sales commission in connection with
purchases of Biotech HOLDRs made in the initial
public offering.
Issuance and cancellation After the initial offering, if you wish to
fees........................ create Biotech HOLDRs by delivering to the
trust the requisite shares of common stock
represented by a round-lot of 100 Biotech
HOLDRs, The Bank of New York as trustee will
charge you an issuance fee of up to $10.00 for
each round-lot of 100 Biotech HOLDRs. If you
wish to cancel your Biotech HOLDRs and withdraw
your underlying securities, The Bank of New
York as trustee will charge you a cancellation
fee of up to $10.00 for each round-lot of 100
Biotech HOLDRs.
Commissions.................. If you choose to deposit underlying securities
in order to receive Biotech HOLDRs after the
conclusion of the initial public offering, you
will not be charged the underwriting fee.
However, in addition to the issuance fee
charged by the trustee described above, you
will be responsible for paying any sales
commission associated with
10
<PAGE>
your purchase of the underlying securities that
is charged by your broker, whether it be
Merrill Lynch, Pierce, Fenner & Smith
Incorporated or another broker.
Custody fees................. The Bank of New York, as trustee and as
custodian, will charge you a quarterly custody
fee of $2.00 for each round-lot of 100 Biotech
HOLDRs to be deducted from any cash dividend or
other cash distributions on underlying
securities received by the trust. With respect
to the aggregate custody fee payable in any
calendar year for each Biotech HOLDR, the
Trustee will waive that portion of the fee
which exceeds the total cash dividends and
other cash distributions received, or to be
received, and payable with respect to such
calendar year.
Rights relating to Biotech You have the right to withdraw the underlying
HOLDRs...................... securities upon request by delivering a round-
lot or integral multiple of a round-lot of
Biotech HOLDRs to the trustee, during the
trustee's business hours, and paying the
cancellation fees, taxes, and other charges.
You should receive the underlying securities no
later than the business day after the trustee
receives a proper notice of cancellation. The
trustee will not deliver fractional shares of
underlying securities. To the extent that any
cancellation of Biotech HOLDRs would otherwise
require the delivery of a fractional share, the
trustee will sell such share in the market and
the trust, in turn, will deliver cash in lieu
of such share. Except with respect to the right
to vote for dissolution of the trust, the
Biotech HOLDRs themselves will not have voting
rights.
Rights relating to the
underlying securities....... You have the right to:
. Receive all shareholder disclosure
materials, including annual and quarterly
reports, distributed by the issuers of the
underlying securities.
. Receive all proxy materials distributed by
the issuers of the underlying securities and
will have the right to instruct the trustee
to vote the underlying securities or may
attend shareholder meetings yourself.
. Receive dividends and other distributions on
the underlying securities, if any are
declared and paid to the trustee by an
issuer of the underlying securities, net of
any applicable taxes or fees.
If you wish to participate in a tender offer
for underlying securities, you must obtain the
underlying securities by surrendering your
Biotech HOLDRs and receiving all of your
underlying securities. For specific information
about obtaining your underlying securities, you
should read the discussion under the caption
"Description of the depositary trust
agreement."
Reconstitution events........
A. If an issuer of underlying securities no
longer has a class of common stock
registered under section 12 of the
Securities Exchange Act of 1934, then its
securities will no longer be an
11
<PAGE>
underlying security and the trustee will
distribute the shares of that company to the
owners of the Biotech HOLDRs.
B. If the SEC finds that an issuer of underlying
securities should be registered as an
investment company under the Investment
Company Act of 1940, and the trustee has
actual knowledge of the SEC finding, then the
trustee will distribute the shares of that
company to the owners of the Biotech HOLDRs.
C. If the underlying securities of an issuer
cease to be outstanding as a result of a
merger, consolidation or other corporate
combination, the trustee will distribute the
consideration paid by and received from the
acquiring company to the beneficial owners of
Biotech HOLDRs, unless the merger,
consolidation or other corporate combination
is between companies that are already
included in the Biotech HOLDRs and the
consideration paid is additional underlying
securities. In this case, the additional
underlying securities will be deposited into
the trust.
D. If an issuer's underlying securities are
delisted from trading on a national
securities exchange or NASDAQ and are not
listed for trading on another national
securities exchange or through NASDAQ within
5 business days from the date such securities
are delisted.
If a reconstitution event occurs, the trustee
will deliver the underlying security to you as
promptly as practicable after the date that the
trustee has knowledge of the occurrence of a
reconstitution event.
Termination events.......... A. The Biotech HOLDRs are delisted from the
American Stock Exchange and are not listed
for trading on another national securities
exchange or through NASDAQ within 5 business
days from the date the Biotech HOLDRs are
delisted.
B. The trustee resigns and no successor trustee
is appointed within 60 days from the date the
trustee provides notice to the initial
depositor of its intent to resign.
C. 75% of beneficial owners of outstanding
Biotech HOLDRs vote to dissolve and liquidate
the trust.
If a termination event occurs, the trustee will
distribute the underlying securities to you as
promptly as practicable after the termination
event.
Federal income tax The federal income tax laws will treat a U.S.
consequences............... holder of Biotech HOLDRs as directly owning the
underlying securities. The Biotech HOLDRs
themselves will not result in any federal tax
consequences separate from the tax consequences
associated with ownership of the underlying
securities.
Listing.....................
The Biotech HOLDRs have been approved for
listing on the American Stock Exchange under the
symbol "BBH," subject to official notice of
issuance. Trading will take place only in round-
lots of 100 Biotech HOLDRs and round-lot
multiples.
12
<PAGE>
A minimum of 150,000 Biotech HOLDRs will be
required to be outstanding when trading begins.
Trading...................... Investors only will be able to acquire, hold,
transfer and surrender a round-lot of 100
Biotech HOLDRs. Bid and ask prices, however,
will be quoted per single Biotech HOLDRs.
Clearance and settlement..... The trust will issue Biotech HOLDRs in book-
entry form. Biotech HOLDRs will be evidenced by
one or more global certificates that the
trustee will deposit with The Depositary Trust
Company, referred to as DTC. Transfers within
DTC will be in accordance with DTC's usual
rules and operating procedures. For further
information see "Description of Biotech
HOLDRs."
13
<PAGE>
THE TRUST
General. This discussion highlights information about the Biotech HOLDRs
trust. You should read this information, information about the depositary trust
agreement as well as the depositary trust agreement before you purchase Biotech
HOLDRs. The material terms of the depositary trust agreement are described in
this prospectus under the heading "Description of the depositary trust
agreement."
The Biotech HOLDRs trust. The trust will be formed pursuant to the
depositary trust agreement, dated as of November 18, 1999. The Bank of New York
will be the trustee. The Biotech HOLDRs trust is not a registered investment
company under the Investment Company Act of 1940.
The Biotech HOLDRs trust is intended to hold deposited shares for the
benefit of owners of Biotech HOLDRs. The trustee will perform only
administrative and ministerial acts. The property of the trust will consist of
the underlying securities and all monies or other property, if any, received by
the trustee. The trust will terminate on December 31, 2039 or earlier if a
termination event occurs.
DESCRIPTION OF BIOTECH HOLDRs
The trust will issue Biotech HOLDRs under the depositary trust agreement
described in this prospectus under the heading "Description of the depositary
trust agreement." After the initial offering, the trust may issue additional
Biotech HOLDRs on a continuous basis when an investor deposits the requisite
underlying securities with the trustee.
You may only acquire, hold, trade and surrender Biotech HOLDRs in a
round-lot of 100 Biotech HOLDRs and round-lot multiples. The trust will only
issue Biotech HOLDRs upon the deposit of the whole shares of underlying
securities that are represented by a round-lot of 100 Biotech HOLDRs. In the
event of a stock split, reverse stock split, or other distribution by the
issuer of an underlying security that results in a fractional share becoming
represented by a round-lot of Biotech HOLDRs, the trust may require a minimum
of more than one round-lot of 100 Biotech HOLDRs for an issuance so that the
trust will always receive whole share amounts for issuance of Biotech HOLDRs.
Biotech HOLDRs will represent your individual and undivided beneficial
ownership interest in the common stock of the specified underlying securities.
The 20 companies selected as part of this receipt program are listed above in
the section entitled "Highlights of Biotech HOLDRs--The Biotech HOLDRs."
Beneficial owners of Biotech HOLDRs will have the same rights and
privileges as they would have if they beneficially owned the underlying
securities outside of the trust. These include the right of investors to
instruct the trustee to vote the common stock, and to receive dividends and
other distributions on the underlying securities, if any are declared and paid
to the trustee by an issuer of an underlying security, as well as the right to
cancel Biotech HOLDRs to receive the underlying securities. See "Description of
the depositary trust agreement." Biotech HOLDRs are not intended to change your
beneficial ownership in the underlying securities under federal securities
laws, including Sections 13(d) and 16(a) of the Securities Exchange Act of
1934.
The trust will not publish or otherwise calculate net asset value per
receipt. Biotech HOLDRs may trade in the secondary market at prices that are
lower than the aggregate value of the corresponding underlying securities. If,
in such case, an owner of Biotech HOLDRs wishes to realize the dollar value of
the underlying securities, that owner will have to cancel the Biotech HOLDRs.
Such cancellation will require payment of fees and expenses as described in
"Description of the depositary trust agreement--Withdrawal of underlying
securities."
Biotech HOLDRs will be evidenced by one or more global certificates that
the trustee will deposit with DTC and register in the name of Cede & Co., as
nominee for DTC. Biotech HOLDRs will be available
14
<PAGE>
only in book-entry form. Owners of Biotech HOLDRs may hold their Biotech HOLDRs
through DTC, if they are participants in DTC, or indirectly through entities
that are participants in DTC.
DESCRIPTION OF THE UNDERLYING SECURITIES
Selection criteria. The underlying securities are the common stocks of a
group of 20 specified companies involved in various segments of the
biotechnology industry and whose common stock is registered under Section 12 of
the Exchange Act. The issuers of the underlying securities are among the 20
largest capitalized, most liquid companies in the biotechnology industry as
measured by market capitalization and trading volume. The following criteria
were used in selecting the underlying securities on October 27, 1999:
. Market capitalization equal to or greater than $840 million;
. Average daily trading volume of at least 200,000 shares over the 60
trading days prior to and including October 27, 1999;
. Average daily dollar volume (that is, the average daily trading
volume multiplied by the closing price on October 27, 1999) of at
least $7.5 million over the 60 trading days prior to and including
October 27, 1999; and
. A trading history of at least 90 calendar days.
The market capitalization of a company is determined by multiplying the price
of its common stock by the number of shares of its common stock that are held
by stockholders. In determining whether a company was to be considered for
inclusion in the Biotech HOLDRs, Merrill Lynch, Pierce, Fenner & Smith
Incorporated examined available public information about the company, including
analysts' reports and other independent market sources. The ultimate
determination of the inclusion of the 20 specified companies, however, rested
solely within the discretion of Merrill Lynch, Pierce, Fenner & Smith
Incorporated.
After the initial deposit, one or more of the issuers of the underlying
securities may no longer be substantially involved in the biotechnology
industry. In this case, the Biotech HOLDRs may no longer consist of securities
issued by companies involved in the biotechnology industry. Merrill Lynch,
Pierce, Fenner & Smith Incorporated will determine, in its sole discretion,
whether the issuer of a particular underlying security remains in the
biotechnology industry and will undertake to make adequate disclosure when
necessary.
Underlying securities. For a list of the underlying securities
represented by Biotech HOLDRs, please refer to "Highlights of Biotech HOLDRs--
The Biotech HOLDRs." If the underlying securities change because of a
reconstitution event, a revised list of underlying securities will be set forth
in a prospectus supplement and will be available from the American Stock
Exchange and through a widely-used electronic information dissemination system
such as Bloomberg or Reuters.
No investigation. In selecting the underlying securities, the trust, the
trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and any affiliate
of these entities, have not performed any investigation or review of the
selected companies, including the public filings by the companies, other than
to the extent required to determine whether the companies satisfied the stated
selection criteria. Accordingly, before you acquire Biotech HOLDRs, you should
consider publicly available financial and other information about the issuers
of the underlying securities. See "Risk factors" and "Where you can find more
information." Investors and market participants should not conclude that the
inclusion of a company in the list is any form of investment recommendation of
that company by the trust, the trustee, Merrill Lynch, Pierce, Fenner & Smith
Incorporated, and any of their affiliates.
General background and historical information. For a brief description of
the business of each of the issuers of the underlying securities and monthly
pricing information showing the historical performance of each underlying
issuer's securities see "Annex A."
15
<PAGE>
The following table and graph set forth the composite performance of all
of the underlying securities represented by a single Biotech HOLDR, measured at
the close of each business day from July 20, 1999, the first date when all of
the underlying securities were publicly traded, to October 27, 1999. The
performance table and graph data are adjusted for any splits that may have
occurred over the measurement period. Past movements of the underlying
securities are not necessarily indicative of future values.
<TABLE>
<CAPTION>
Biotech
1999 HOLDRs
- ---- -------
<S> <C>
July 20......... 81.40
July 21......... 83.70
July 22......... 81.77
July 23......... 81.72
July 26......... 80.37
July 27......... 82.82
July 28......... 83.24
July 29......... 81.96
July 30......... 85.63
</TABLE>
<TABLE>
<CAPTION>
Biotech
1999 HOLDRs
- ---- -------
<S> <C>
August 2........ 87.65
August 3........ 86.96
August 4........ 86.38
August 5........ 86.25
August 6........ 85.57
August 9........ 86.82
August 10....... 85.87
August 11....... 89.16
August 12....... 91.51
August 13....... 95.50
August 16....... 96.40
August 17....... 94.22
August 18....... 94.10
August 19....... 92.46
August 20....... 94.40
August 23....... 100.08
August 24....... 99.68
August 25....... 100.62
August 26....... 98.35
August 27....... 97.77
August 30....... 97.41
August 31....... 97.77
</TABLE>
<TABLE>
<CAPTION>
Biotech
1999 HOLDRs
- ---- -------
<S> <C>
September 1..... 100.46
September 2..... 98.48
September 3..... 102.39
September 7..... 102.85
September 8..... 102.17
September 9..... 103.27
September 10.... 102.54
September 13.... 102.50
September 14.... 100.10
September 15.... 95.69
September 16.... 96.09
September 17.... 98.05
September 20.... 98.16
September 21.... 95.69
September 22.... 98.27
September 23.... 95.01
September 24 ... 92.33
September 27.... 92.88
September 28.... 91.02
September 29.... 91.34
September 30.... 89.88
</TABLE>
<TABLE>
<CAPTION>
Biotech
1999 HOLDRs
- ---- -------
<S> <C>
October 1....... 92.02
October 4....... 92.58
October 5....... 92.13
October 6....... 97.74
October 7....... 99.65
October 8....... 97.81
October 11...... 98.52
October 12...... 95.36
October 13...... 93.87
October 14...... 92.96
October 15...... 88.02
October 18...... 86.70
October 19...... 89.73
October 20...... 91.85
October 21...... 90.68
October 22...... 89.91
October 25...... 90.12
October 26...... 88.38
October 27...... 88.09
</TABLE>
[GRAPH APPEARS HERE]
16
<PAGE>
DESCRIPTION OF THE DEPOSITARY TRUST AGREEMENT
General. The depositary trust agreement, dated as of November 18, 1999,
among Merrill Lynch, Pierce, Fenner & Smith Incorporated, The Bank of New York,
as trustee, other depositors and the owners of the Biotech HOLDRs, provides
that Biotech HOLDRs will represent an owner's undivided beneficial ownership
interest in the common stock of the underlying companies.
The trustee. The Bank of New York will serve as trustee. The Bank of New
York, which was founded in 1784, was New York's first bank and is the oldest
bank in the country still operating under its original name. The Bank is a
state-chartered New York banking corporation and a member of the Federal
Reserve System. The Bank conducts a national and international wholesale
banking business and a retail banking business in the New York City, New Jersey
and Connecticut areas, and provides a comprehensive range of corporate and
personal trust, securities processing and investment services.
Issuance, transfer and surrender of Biotech HOLDRs. You may create and
cancel Biotech HOLDRs only in round-lots of 100 Biotech HOLDRs. You may create
Biotech HOLDRs by delivering to the trustee the requisite underlying
securities. The trust will only issue Biotech HOLDRs upon the deposit of the
whole shares represented by a round-lot of 100 Biotech HOLDRs. In the event
that an issuer of underlying securities distributes a fractional share that is
represented in a round-lot of Biotech HOLDRs, the trust may require a minimum
of more than one round-lot of 100 Biotech HOLDRs for an issuance so that the
trust will always receive whole share amounts for issuance of Biotech HOLDRs.
Similarly, you must surrender Biotech HOLDRs in integral multiples of 100
Biotech HOLDRs to withdraw deposited shares from the trust. The trustee will
not deliver fractional shares of underlying securities, to the extent that any
cancellation of Biotech HOLDRs would otherwise require the delivery of
fractional shares, the trust will deliver cash in lieu of such shares. You may
request withdrawal of your deposited shares during the trustee's normal
business hours. The trustee expects that in most cases it will deliver your
deposited shares within one business day of your withdrawal request.
Voting rights. The trustee will deliver you proxy soliciting materials
provided by issuers of the deposited shares so as to permit you to give the
trustee instructions as to how to vote on matters to be considered at any
annual or special meetings held by issuers of the underlying securities.
Under the depositary trust agreement, the beneficial owners of Biotech
HOLDRs, other than Merrill Lynch, Pierce, Fenner & Smith Incorporated owning
Biotech HOLDRs for its own proprietary account as principal, will have the
right to vote to dissolve and liquidate the trust.
Distributions. You will be entitled to receive, net of trustee fees,
distributions of cash, including dividends, securities or property, if any,
made with respect to the underlying securities. The trustee will use its
reasonable efforts to ensure that it distributes these distributions as
promptly as practicable after the date on which it receives the distribution.
Therefore, you may receive your distributions substantially later than you
would have had you held the underlying securities directly. You will be
obligated to pay any tax or other charge that may become due with respect to
Biotech HOLDRs. The trustee may deduct the amount of any tax or other
governmental charge from a distribution before making payment to you. In
addition, the trustee will deduct its quarterly custody fee of $2.00 for each
round-lot of 100 Biotech HOLDRs from quarterly dividends, if any, paid to the
trustee by the issuers of the underlying securities. With respect to the
aggregate custody fee payable in any calendar year for each Biotech HOLDR, the
trustee will waive that portion of the fee which exceeds the total cash
dividends and other cash distributions received, or to be received, and payable
with respect to such calendar year.
Record dates. With respect to dividend payments and voting instructions,
the trustee expects to fix the trust's record dates as close as possible to the
record date fixed by the issuer of the underlying securities.
17
<PAGE>
Shareholder communications. The trustee promptly will forward to you all
shareholder communications that it receives from issuers of the underlying
securities.
Withdrawal of underlying securities. You may surrender your Biotech
HOLDRs and receive underlying securities during the trustee's normal business
hours and upon the payment of applicable fees, taxes or governmental charges,
if any. You should receive your underlying securities no later than the
business day after the trustee receives your request. If you surrender Biotech
HOLDRs in order to receive underlying securities, you will pay to the trustee a
cancellation fee of up to $10.00 per round-lot of 100 Biotech HOLDRs.
Further issuances of Biotech HOLDRs. The depositary trust agreement
provides for further issuances of Biotech HOLDRs on a continuous basis without
your consent.
Reconstitution events. The depositary trust agreement provides for the
automatic distribution of underlying securities to you in four circumstances.
A. If an issuer of underlying securities no longer has a class of
common stock registered under section 12 of the Securities
Exchange Act of 1934, then its securities will no longer be an
underlying security and the trustee will distribute the shares
of that company to the owners of the Biotech HOLDRs.
B. If the SEC finds that an issuer of underlying securities should
be registered as an investment company under the Investment
Company Act of 1940, and the trustee has actual knowledge of
the SEC finding, then the trustee will distribute the shares of
that company to the owners of the Biotech HOLDRs.
C. If the underlying securities of an issuer cease to be
outstanding as a result of a merger, consolidation or other
corporate combination, the trustee will distribute the
consideration paid by and received from the acquiring company
to the beneficial owners of Biotech HOLDRs, unless the merger,
consolidation or other corporate combination is between
companies that are already included in the Biotech HOLDRs and
the consideration paid is additional underlying securities. In
this case, the additional underlying securities will be
deposited into the trust.
D. If an issuer's underlying securities are delisted from trading
on a national securities exchange or NASDAQ and are not listed
for trading on another national securities exchange or through
NASDAQ within 5 business days from the date such securities are
delisted.
If a reconstitution event occurs, the trustee will deliver the underlying
security to you as promptly as practicable after the date that the trustee has
knowledge of the occurrence of a reconstitution event.
Termination of the trust. The trust will terminate if the trustee resigns
and no successor trustee is appointed by the initial depositor within 60 days
from the date the trustee provides notice to the initial depositor of its
intent to resign. Upon termination, the beneficial owners of Biotech HOLDRs
will surrender their Biotech HOLDRs as provided in the depositary trust
agreement, including payment of any fees of the trustee or applicable taxes or
governmental charges due in connection with delivery to the owners of the
underlying securities. The trust also will terminate if Biotech HOLDRs are
delisted from the American Stock Exchange and are not listed for trading on
another national securities exchange or through NASDAQ within 5 business days
from the date the Biotech HOLDRs are delisted. Finally, the trust will
terminate if 75% of the owners of outstanding Biotech HOLDRs other than Merrill
Lynch, Pierce, Fenner & Smith Incorporated vote to dissolve and liquidate the
trust.
If a termination event occurs, the trustee will distribute the underlying
securities to you as promptly as practicable after the termination event
occurs.
18
<PAGE>
Amendment of the depositary trust agreement. The trustee and the initial
depositor may amend any provisions of the depositary trust agreement without
the consent of any other depositor or any of the owners of the Biotech HOLDRs.
Promptly after the execution of any amendment to the agreement, the trustee
must furnish or cause to be furnished written notification of the substance of
the amendment to each owner of Biotech HOLDRs. Any amendment that imposes or
increases any fees or charges, subject to exceptions, or that otherwise
prejudices any substantial existing right of the owners of Biotech HOLDRs will
not become effective until 30 days after notice of the amendment is given to
the owners of Biotech HOLDRs.
Issuance and cancellation fees. After the initial public offering, the
trust expects to issue more Biotech HOLDRs. If you wish to create Biotech
HOLDRs by delivering to the trust the requisite underlying securities, the
trustee will charge you an issuance fee of up to $10.00 for each round-lot of
100 Biotech HOLDRs. If you wish to cancel your Biotech HOLDRs and withdraw your
underlying securities, the trustee will charge you a cancellation fee of up to
$10.00 for each round-lot of 100 Biotech HOLDRs issued. The trustee may
negotiate either of these fees depending on the volume, frequency and size of
the issuance or cancellation transactions.
Commissions. If you choose to create Biotech HOLDRs after the conclusion
of the initial public offering, you will not be charged the underwriting fee.
However, in addition to the issuance and cancellation fees described above, you
will be responsible for paying any sales commissions associated with your
purchase of the underlying securities that is charged by your broker, whether
it be Merrill Lynch, Pierce, Fenner & Smith Incorporated or another broker.
Custody fees. The Bank of New York, as trustee and as custodian, will
charge you a quarterly custody fee of $2.00 for each round-lot of 100 Biotech
HOLDRs to be deducted from any dividend payments or other cash distributions on
underlying securities received by the trustee. With respect to the aggregate
custody fee payable in any calendar year for each Biotech HOLDR, the Trustee
will waive that portion of the fee which exceeds the total cash dividends and
other cash distributions received, or to be received, and payable with respect
to such calendar year. The trustee cannot recapture unpaid custody fees from
prior years.
Address of the trustee. The Bank of New York, ADR Department, 101 Barclay
Street, New York, New York 10286.
Governing law. The depositary trust agreement and Biotech HOLDRs will be
governed by the laws of the State of New York. The trustee will provide the
depositary trust agreement to any owner of the underlying securities free of
charge upon written request.
Duties and immunities of the trustee. The trustee will assume no
responsibility or liability for, and makes no representations as to, the
validity or sufficiency, or as to the accuracy of the recitals, if any, set
forth in the Biotech HOLDRs.
The trustee undertakes to perform only those duties as are specifically
set forth in the depositary trust agreement. Subject to the preceding sentence,
the trustee will be liable for its own negligence or misconduct except for good
faith errors in judgment so long as the trustee was not negligent in
ascertaining the relevant facts.
19
<PAGE>
FEDERAL INCOME TAX CONSEQUENCES
General
The following is a summary of the U.S. federal income tax consequences
relating to the Biotech HOLDRs for:
. a citizen or resident of the United States, a corporation or
partnership created or organized in the United States or under the
laws of the United States, an estate, the income of which is
includible in gross income for U.S. federal income tax purposes
regardless of its source, or a trust if a court within the United
States is able to exercise primary supervision over the
administration of the trust and one or more U.S. persons have the
authority to control all substantial decisions of the trust (a
"U.S. receipt holder"), and
. any person other than a U.S. receipt holder (a "Non-U.S. receipt
holder").
This summary is based upon laws, regulations, rulings and decisions
currently in effect, all of which are subject to change, possibly on a
retroactive basis. The discussion does not deal with all U.S. federal income
tax consequences applicable to all categories of investors, some of which may
be subject to special rules. In addition, this summary generally is limited to
investors who will hold the Biotech HOLDRs as "capital assets" (generally,
property held for investment) within the meaning of Section 1221 of the
Internal Revenue Code of 1986, as amended. We suggest that you consult with
your own tax advisor.
Taxation of the trust
The trust will provide for flow through tax consequences as it will be
treated as a grantor trust or custodial arrangement for United States federal
income tax purposes.
Taxation of Biotech HOLDRs
A receipt holder purchasing and owning Biotech HOLDRs will be treated,
for U.S. federal income tax purposes, as directly owning a proportionate share
of the underlying securities represented by Biotech HOLDRs. Consequently, if
there is a taxable cash distribution on an underlying security, a holder will
recognize income with respect to the distribution at the time the distribution
is received by the trustee, not at the time that the holder receives the cash
distribution from the trustee.
A receipt holder will determine its initial tax basis in each of the
underlying securities by allocating the purchase price for the Biotech HOLDRs
among the underlying securities based on their relative fair market values at
the time of purchase. Similarly, when a holder sells a receipt, it will
determine the amount realized with respect to each security by allocating the
sales price among the underlying securities based on their relative fair market
values at the time of sale. A holder's gain or loss with respect to each
security will be computed by subtracting its basis in the security from the
amount realized on the security. With respect to purchases of Biotech HOLDRs
for cash in the secondary market, a receipt holder's aggregate tax basis in
each of the underlying securities will be equal to the purchase price of the
Biotech HOLDRs. Similarly, with respect to sales of Biotech HOLDRs for cash in
the secondary market, the amount realized with respect to a sale of Biotech
HOLDRs will be equal to the aggregate amount realized with respect to each of
the underlying securities.
The distribution of any securities by the trust upon the surrender of
Biotech HOLDRs, the occurrence of a reconstitution event, or a termination
event will not be a taxable event. The receipt holders holding period with
respect to the distributed securities will include the period that the holder
held the securities through the trust.
20
<PAGE>
Brokerage fees and custodian fees
The brokerage fee incurred in purchasing a receipt will be treated as
part of the cost of the underlying securities. Accordingly, a holder includes
this fee in its tax basis in the underlying securities. A holder will allocate
the brokerage fee among the underlying securities using either a fair market
value allocation or pro rata based on the number of shares of each underlying
security. Similarly, the brokerage fee incurred in selling Biotech HOLDRs will
reduce the amount realized with respect to the underlying securities.
A holder will be required to include in its income the full amount of
dividends paid on the underlying securities, even though the depositary trust
agreement provides that the custodian fees will be deducted directly from any
dividends paid. These custodian fees will be treated as an expense incurred in
connection with a holder's investment in the underlying securities and may be
deductible. If a holder is an individual, estate or trust, however, the
deduction of its share of custodian fees will be a miscellaneous itemized
deduction that may be disallowed in whole or in part.
Non-U.S. receipt holders
Non-U.S. receipt holders should consult their tax advisors regarding U.S.
withholding and other taxes which may apply to an investment in the underlying
securities.
ERISA CONSIDERATIONS
Any plan fiduciary which proposes to have a plan acquire Biotech HOLDRs
should consult with its counsel with respect to the potential applicability of
ERISA and the Code to this investment and whether any exemption would be
applicable and determine on its own whether all conditions have been satisfied.
Moreover, each plan fiduciary should determine whether, under the general
fiduciary standards of investment prudence and diversification, an acquisition
of Biotech HOLDRs is appropriate for the plan, taking into account the overall
investment policy of the plan and the composition of the plan's investment
portfolio.
PLAN OF DISTRIBUTION
In accordance with the depository trust agreement, the trust will issue
to Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Merrill Lynch,
Pierce, Fenner & Smith Incorporated will deposit the underlying securities to
receive Biotech HOLDRs. Merrill Lynch & Co., as underwriter, proposes to offer
the Biotech HOLDRs to the public at the offering price set forth on the cover
page of this prospectus. Merrill Lynch expects the trust to deliver the initial
distribution of Biotech HOLDRs against deposit of the underlying securities in
New York, New York on November 26, 1999. After the initial offering, the public
offering price, concession and discount may be changed. The trust will continue
to issue Biotech HOLDRs, in connection with deposits of underlying securities.
Merrill Lynch will not make sales to discretionary accounts without the prior
written approval of a purchaser of the Biotech HOLDRs.
Merrill Lynch has from time to time provided investment banking and other
financial services to certain of the issuers of the underlying securities and
expects in the future to provide these services, for which it has received and
will receive customary fees and commissions. It also may have served as
counterparty in other transactions with certain of the issuers of the
underlying securities.
Merrill Lynch, Pierce, Fenner & Smith Incorporated may use this
prospectus, as updated from time to time, in connection with offers and sales
related to market-making transactions in the Biotech HOLDRs. Merrill Lynch,
Pierce, Fenner & Smith Incorporated may act as principal or agent in such
transactions. Market-making sales will be made at prices related to prevailing
market prices at the time of sale.
Merrill Lynch, Pierce, Fenner & Smith Incorporated has agreed to
indemnify the trustee against certain civil liabilities related to acts
performed or not performed by the trustee in accordance with the depositary
trust
21
<PAGE>
agreement or periodic reports filed or not filed with the SEC with respect to
the Biotech HOLDRs. Should a court determine not to enforce the indemnification
provision, Merrill Lynch, Pierce, Fenner & Smith Incorporated also has agreed
to contribute to payments the trustee may be required to make with respect to
such liabilities.
YEAR 2000
The trustee's Year 2000 compliance program consists of updating major
trustee-owned application systems, business-area supported systems, and the
trustee's proprietary customer software and evaluating the Year 2000 compliance
efforts of vendors of major vendor-supplied systems. The trustee's compliance
efforts have also considered the Year 2000 readiness of its global sub-
custodians, major service providers, correspondents, business partners, and
borrowers. The current focus is to monitor continued preparedness and
contingency planning. While contingency planning has been defined as part of
the Year 2000 compliance program, all new measures have been incorporated into
the trustee's existing Business Continuity Plans.
The trustee divided its major proprietary applications systems into three
business line groups. The applications in each group were subjected to a phased
process of assessment, renovation, certification testing, and implementation.
All critical systems have completed all phases. A program is in place to
continue to monitor critical systems to prevent Y2K problems from being
reintroduced. Major business-line products have been made available in isolated
future-dated environments for selected customers to test their interfaces and
to assure themselves of the trustee's compliance. The trustee is satisfied with
the results of testing with customers and agencies. Continued participation at
the request of the agencies and customers will continue as required.
Remediation of the trustee's proprietary customer software has been
completed. Installation on client desktop computers is substantially complete.
Customers have been advised of their obligation to assure that their
environments are compliant in order for the trustees's software to function
correctly during and after the century date change.
The trustee has substantially completed an evaluation of its significant
business partners, including other financial services providers,
correspondents, counterparties, sub-custodians, vendors and settlement
agencies, for the purpose of assessing their Year 2000 compliance. The trustee
is currently satisfied with the information it has received concerning the
progress and Year 2000 readiness programs of each significant third party. The
trustee will continue to monitor the readiness and progress of these parties
throughout 1999. The trustee has replaced certain service providers that were
seen as not managing the Year 2000 issue adequately.
The trustee considers Year 2000 readiness in its credit decisions and
factors this into borrower ratings. Based on a review of significant obligors,
the trustee believes that exposure to obligor Year 2000 problems does not
present a material risk to the trustee.
The trustee's personal computers considered to be critical to the
trustee's operations have been upgraded. Upgrading of physical facilities that
is considered critical to the trustee's operations to Year 2000 readiness is
expected to be completed by the end of November 1999.
The trustee's contingency plans relating to Year 2000 issues include the
identification and assessment of the impact of various worst case scenarios on
the critical operational components for each of the trustee's business units.
The trustee has reviewed the applicability of its current contingency plans,
which include creation of an information center, establishment of special rapid
response technology teams, scheduling availability of key personnel, testing
and simulation activities, offsite data center facilities, and emergency backup
power. These plans, with minor modification, have been determined to be
adequate to mitigate Year 2000 related risks. The information center, which has
been established as a repository and focus for analysis of information, will
publish the status of the organization internally and externally during
critical periods. It is also authorized to requisition and deploy resources as
needed to address unanticipated situations.
22
<PAGE>
Overall the trustee's Year 2000 compliance program is on or ahead of
schedule to meet the needs of its customers and compliance deadlines defined by
its regulators. The estimated cost of the Year 2000 project is approximately
$82 million. In the first nine months of 1999 the trustee spent $16 million on
making computer systems Year 2000 compliant. Total expenses since 1997 have
been $67 million.
A material Year 2000 problem could result in an interruption in, or a
failure of, certain normal business activities or operations. Such problems
could materially and adversely affect the trustee's results of operations,
liquidity and financial condition. Due to the general uncertainty inherent in
the year 2000 problem, resulting in part from the uncertainty of the Year 2000
readiness of suppliers, customers and other business partners, as well as
entities with which the trustee does not have direct business relations, the
trustee is unable to determine at this time whether the consequences of the
Year 2000 failures will have a material impact on the trustee's results of
operations, liquidity or financial condition. The Year 2000 compliance program
is intended to significantly reduce the trustee's level of uncertainty about
the Year 2000 problem and, in particular, about the Year 2000 compliance and
readiness of its material business partners. The trustee believes that, with
completion of its Year 2000 compliance program as scheduled, the possibility of
significant interruptions of normal operations should be reduced. However,
because of the unprecedented nature of this issue, there can be no certainty as
to its impact.
LEGAL MATTERS
Legal matters, including the validity of the Biotech HOLDRs have been
passed upon for Merrill Lynch, Pierce, Fenner & Smith Incorporated, the initial
depositor and the underwriter, by Shearman & Sterling, New York, New York.
Shearman & Sterling, as special U.S. tax counsel to the trust, also has
rendered an opinion regarding the material federal income tax consequences
relating to the Biotech HOLDRs.
WHERE YOU CAN FIND MORE INFORMATION
Merrill Lynch, Pierce, Fenner & Smith Incorporated has filed a
registration statement on Form S-1 with the SEC covering the Biotech HOLDRs.
While this prospectus is a part of the registration statement, it does not
contain all the exhibits filed as part of the registration statement. You
should consider reviewing the full text of those exhibits.
The registration statement is available over the Internet at the SEC's
web site at http://www.sec.gov. You also may read and copy the registration
statement at the SEC's public reference rooms in Washington, D.C., New York,
New York and Chicago, Illinois. Please call the SEC at 1-800-SEC-0330 for more
information on the public reference rooms and their copy charges. Merrill
Lynch, Pierce, Fenner & Smith Incorporated will not and the trust may not be
subject to the requirements of the Exchange Act and accordingly may not file
periodic reports.
Because the common stock of the issuers of the underlying securities is
registered under the Exchange Act, the issuers of the underlying securities are
required to file periodically financial and other information specified by the
SEC. For more information about the issuers of the underlying securities,
information provided to or filed with the SEC by the issuers of the underlying
securities with respect to their registered securities can be inspected at the
SEC's public reference facilities or accessed through the SEC's web site
referenced above. In addition, information regarding the issuers of the
underlying securities may be obtained from other sources including, but not
limited to, press releases, newspaper articles and other publicly disseminated
information.
The trust and Merrill Lynch, Pierce, Fenner & Smith Incorporated and its
affiliates are not affiliated with the issuers of the underlying securities,
and the issuers of the underlying securities have no obligations with respect
to Biotech HOLDRs. This prospectus relates only to Biotech HOLDRs and does not
relate to the
23
<PAGE>
common stock or other securities of the issuers of the underlying securities.
The information in this prospectus regarding the issuers of the underlying
securities has been derived from the publicly available documents described in
the preceding paragraph. We have not participated in the preparation of these
documents or made any due diligence inquiries with respect to the issuers of
the underlying securities in connection with Biotech HOLDRs. We make no
representation that these publicly available documents or any other publicly
available information regarding the issuers of the underlying securities are
accurate or complete. Furthermore, we cannot assure you that all events
occurring prior to the date of this prospectus, including events that would
affect the accuracy or completeness of the publicly available documents
described in the preceding paragraph, that would affect the trading price of
the common stock of the issuers of the underlying securities, and therefore the
offering and trading prices of the Biotech HOLDRs, have been publicly
disclosed.
24
<PAGE>
ANNEX A
This annex forms an integral part of the prospectus.
The following tables provide a brief description of the business of each
of the issuers of the underlying securities and set forth the split-adjusted
closing market prices, as reported on the applicable primary trading market, of
each of the underlying securities in each month during 1994, 1995, 1996, 1997,
1998 and 1999 through October 1999. All market prices in excess of one dollar
are rounded to the nearest one sixty-fourth dollar. An asterisk (*) denotes
that no shares of the issuer were outstanding during that month. The historical
prices of the underlying securities should not be taken as an indication of
future performance.
AFFYMETRIX, INC.
Affymetrix, Inc. develops and manufactures DNA chip technology.
Affymetrix's "GeneChip" system acquires, analyzes, and manages genetic
information in order to improve the diagnosis, monitoring and treatment of
disease. Affymetrix markets its products directly, and through an exclusive
sales agent, to pharmaceutical and biotechnology companies, academic research
centers and clinical reference laboratories.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- ------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January * January * January * January 29 1/4 January 27 13/16 January 41 1/2
February * February * February * February 28 February 31 3/8 February 38 3/4
March * March * March * March 27 March 34 13/16 March 34 13/16
April * April * April * April 25 April 31 1/2 April 40 7/8
May * May * May * May 30 3/4 May 26 7/8 May 35 1/8
June * June * June * June 34 3/4 June 24 1/16 June 49 3/8
July * July * July * July 32 5/8 July 26 7/8 July 72 3/4
August * August * August * August 33 1/2 August 16 1/2 August 85 5/8
September * September * September * September 46 September 25 3/4 September 98 7/16
October * October * October 18 1/4 October 36 5/8 October 24 1/2 October 88 1/8
November * November * November 19 1/2 November 34 3/8 November 25
December * December * December 20 3/16 December 31 1/8 December 24 3/8
The closing price on November 22, 1999 was 89 1/4.
ALKERMES, INC.
Alkermes, Inc. develops products based on drug delivery technologies.
Alkermes focuses on controlled, sustained release of injectable drugs, as well
as the delivery of drugs into the brain past the blood-brain barrier. Alkermes
also focuses on the oral delivery of drugs, and the development of
pharmaceutical products based on pulmonary drug delivery technologies.
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- ------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 8 January 2 3/4 January 9 7/8 January 23 1/4 January 24 1/4 January 31 1/8
February 7 3/8 February 2 29/32 February 9 7/8 February 24 7/8 February 23 3/16 February 28 1/16
March 7 March 2 3/4 March 9 1/8 March 14 March 24 7/8 March 27 1/4
April 5 3/4 April 2 7/8 April 10 7/8 April 11 April 23 7/8 April 26 3/4
May 5 1/4 May 3 1/16 May 15 9/16 May 16 1/2 May 21 7/8 May 24 3/4
June 4 5/8 June 3 7/8 June 12 1/4 June 14 1/2 June 17 31/32 June 23 1/8
July 3 1/4 July 8 5/8 July 12 3/8 July 15 7/8 July 19 3/4 July 26 1/8
August 3 3/4 August 6 7/8 August 13 1/4 August 18 5/8 August 10 15/16 August 37 1/8
September 3 9/16 September 6 1/2 September 15 5/8 September 20 5/8 September 14 9/16 September 28 13/16
October 3 1/2 October 6 1/2 October 13 1/4 October 22 3/4 October 19 1/2 October 35 5/16
November 3 1/4 November 5 7/8 November 14 1/8 November 19 3/4 November 18 3/8
December 2 1/8 December 7 15/16 December 23 1/4 December 19 7/8 December 22 3/16
</TABLE>
The closing price on November 22, 1999 was 45.
A-1
<PAGE>
AMGEN INC.
Amgen Inc. discovers, develops, manufactures and markets human
therapeutics based on advanced cellular and molecular biology. Amgen focuses
its research on secreted protein and small molecule therapeutics, with
particular emphasis on neuroscience and cancer. Amgen concentrates product
development in the areas of hematology, cancer, infectious disease,
endocrinology, neurobiology and inflammation. Amgen effected a 2-for-1 stock
split on its common stock in the form of a stock dividend to shareholders of
record on November 5, 1999. The stock began trading on a split-adjusted basis
on November 22, 1999. The following table is adjusted to account for this stock
split.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- -------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 6 3/32 January 7 61/64 January 15 1/32 January 14 3/32 January 12 1/2 January 31 61/64
February 5 7/32 February 8 5/8 February 14 15/16 February 15 9/32 February 13 9/32 February 31 7/32
March 4 25/32 March 8 27/64 March 14 17/32 March 13 31/32 March 15 7/32 March 37 7/16
April 5 1/16 April 9 3/32 April 14 3/8 April 14 23/32 April 14 29/32 April 30 23/32
May 5 53/64 May 9 1/16 May 14 7/8 May 16 23/32 May 15 1/8 May 31 5/8
June 5 23/64 June 10 1/16 June 13 1/2 June 14 17/32 June 16 11/32 June 30 7/16
July 6 7/32 July 10 41/64 July 13 21/32 July 14 11/16 July 18 23/64 July 38 7/16
August 6 19/32 August 11 31/32 August 14 9/16 August 12 25/64 August 15 7/32 August 41 19/32
September 6 21/32 September 12 15/32 September 15 25/32 September 11 63/64 September 18 57/64 September 40 3/4
October 6 31/32 October 12 October 15 21/64 October 12 5/16 October 19 41/64 October 39 7/8
November 7 19/64 November 12 13/32 November 15 7/32 November 12 25/32 November 18 13/16
December 7 3/8 December 14 27/32 December 13 19/32 December 13 17/32 December 26 9/64
</TABLE>
The closing price on November 22, 1999 was 48 3/16.
BIOCHEM PHARMA INC.
BioChem Pharma Inc. researches and develops products for the prevention,
detection and treatment of human diseases. In particular, BioChem focuses its
research and development in the antiviral, anticancer, pain control, vaccine
and the diagnostic product areas. One of the significant products being
developed by BioChem is to be used for the treatment of patients with the HIV
infection and forms of hepatitis B. BioChem markets and sells its products
through its own sales and marketing force and through co-promotion and
licensing arrangements with third parties.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- -------- --------- -------- --------- -------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 6 15/32 January 7 25/64 January 21 7/8 January 27 29/32 January 20 25/64 January 28 11/16
February 5 17/32 February 6 27/32 February 23 February 26 23/64 February 22 5/16 February 24 9/16
March 4 31/32 March 7 61/64 March 20 25/64 March 21 3/8 March 24 3/64 March 21 5/16
April 4 17/32 April 7 61/64 April 22 5/8 April 17 57/64 April 25 19/64 April 20 3/4
May 4 17/32 May 8 57/64 May 22 7/8 May 24 39/64 May 26 7/64 May 19 1/8
June 4 9/32 June 10 7/8 June 18 61/64 June 22 1/8 June 26 1/2 June 18 3/4
July 4 13/32 July 12 5/16 July 14 55/64 July 28 23/32 July 23 15/16 July 21 5/8
August 5 7/32 August 14 63/64 August 17 9/32 August 25 51/64 August 15 5/16 August 25 59/64
September 5 5/32 September 15 27/32 September 19 61/64 September 31 21/64 September 18 3/8 September 23 15/16
October 5 15/32 October 19 1/64 October 21 3/16 October 24 59/64 October 21 11/16 October 20 9/16
November 5 29/32 November 19 9/64 November 21 19/64 November 25 23/64 November 24 3/8
December 6 7/32 December 19 61/64 December 24 63/64 December 20 49/64 December 28 5/8
</TABLE>
The closing price on November 22, 1999 was 24.
A-2
<PAGE>
BIOGEN, INC.
Biogen, Inc. develops, manufactures and markets drugs for human health
care. Biogen develops products used for the treatment of multiple sclerosis and
kidney, inflammatory and cardiovascular diseases. Biogen's research is focused
on molecular and cell biology, immunology and protein chemistry which can lead
to developments in the understanding of disease processes and, as a result, the
creation of new pharmaceuticals, developmental biology and gene therapy. Biogen
sells "AVONEX" to treat relapsing forms of multiple sclerosis, hepatitis B
vaccines and diagnostic equipment.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- -------- --------- -------- --------- -------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 13 1/32 January 9 3/32 January 17 9/16 January 23 3/8 January 20 9/16 January 49 1/8
February 10 31/32 February 10 5/16 February 16 11/32 February 24 5/8 February 22 1/16 February 48 1/16
March 8 11/16 March 9 15/16 March 14 7/8 March 18 11/16 March 24 3/32 March 57 5/32
April 8 15/16 April 9 13/16 April 16 15/32 April 16 April 22 3/16 April 47 17/32
May 8 3/8 May 10 3/8 May 15 1/8 May 16 19/32 May 22 May 54 9/16
June 7 5/32 June 11 1/8 June 13 23/32 June 16 15/16 June 24 1/2 June 64 5/16
July 10 7/8 July 11 1/2 July 15 9/32 July 19 1/4 July 27 13/16 July 68 13/16
August 12 19/32 August 13 11/16 August 17 7/16 August 19 11/16 August 23 1/8 August 76 3/4
September 13 5/8 September 15 September 19 September 16 7/32 September 32 29/32 September 78 13/16
October 12 1/4 October 15 5/16 October 18 5/8 October 16 3/4 October 34 3/4 October 74 1/8
November 9 11/16 November 13 5/8 November 19 1/8 November 17 1/2 November 37 15/16
December 10 7/16 December 15 3/8 December 19 3/8 December 18 3/16 December 41 1/2
</TABLE>
The closing price on November 22, 1999 was 79 1/16.
CELERA GENOMICS
Celera Genomics generates, sells, and supports information about genes
and related information management and analysis software. Celera Genomics
generates and commercializes genomic information to assist the understanding of
biological processes and to assist pharmaceutical and biotechnology research
entities in the drug development process and the interrelationship between
genetic variability, disease and drug response. Currently, Celera Genomics'
products include technologies that allow for the analysis of gene expression
which can assist in the identification of genes that are affected by a disease
or a particular treatment. Celera Genomics is also involved in the development
of genotyping and genomic services for plant and animal breeding programs.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- ------- --------- ------- --------- -------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January * January * January * January * January * January *
February * February * February * February * February * February *
March * March * March * March * March * March *
April * April * April * April * April * April 26 3/8
May * May * May * May * May * May 16 3/4
June * June * June * June * June * June 15 7/8
July * July * July * July * July * July 26 1/4
August * August * August * August * August * August 28 7/16
September * September * September * September * September * September 40
October * October * October * October * October * October 39 1/8
November * November * November * November * November *
December * December * December * December * December *
</TABLE>
The closing price on November 22, 1999 was 51 5/16.
A-3
<PAGE>
CHIRON CORPORATION
Chiron Corporation is involved in biopharmaceuticals (pharmaceutical
products derived from a biological process rather than from
an inorganic chemical process), vaccines and blood testing. Chiron's products
include: "Proleukin," which is marketed as a treatment for metastatic renal
cell carcinoma and metastatic melanoma; vaccines for, among other things,
tetanus, meningococcus, flu and measles; tests used for screening and testing
blood in blood banks; and treatment of diphtheria.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- -------- --------- -------- --------- -------- --------- ------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 23 25/32 January 17 1/8 January 28 3/4 January 18 5/8 January 17 15/16 January 22 3/4
February 19 3/8 February 15 3/16 February 27 25/32 February 20 3/4 February 19 3/16 February 21 1/16
March 16 7/16 March 13 7/16 March 24 9/16 March 18 5/8 March 20 15/16 March 21 15/16
April 16 7/32 April 13 13/16 April 24 3/32 April 18 3/4 April 19 3/8 April 20 1/8
May 16 May 12 15/16 May 26 1/4 May 18 7/8 May 18 1/16 May 21 1/8
June 13 11/16 June 16 1/4 June 24 1/2 June 20 7/8 June 15 11/16 June 20 3/4
July 13 7/16 July 19 3/4 July 22 July 21 July 17 July 25 1/16
August 17 7/16 August 22 7/16 August 19 5/8 August 22 3/8 August 14 3/8 August 32 1/8
September 16 5/8 September 22 5/8 September 19 September 22 5/8 September 19 7/8 September 27 11/16
October 16 27/32 October 22 3/4 October 22 7/8 October 19 1/4 October 22 1/2 October 28 9/16
November 19 5/16 November 25 3/16 November 19 3/8 November 18 3/16 November 22 5/8
December 20 3/32 December 27 5/8 December 18 5/8 December 17 December 26 3/16
</TABLE>
The closing price on November 22, 1999 was 34 15/16.
ENZON, INC.
Enzon, Inc. develops, manufactures and markets enhanced therapeutics for
life-threatening diseases. Enzon commercializes its technologies by developing
and distributing products in cooperation with strategic partners. Enzon has
developed products to treat children who are born without fully developed
immune systems and that are used in the treatment of a certain form of
leukemia.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- ------- --------- ------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 4 7/8 January 2 January 3 11/16 January 2 61/64 January 5 1/2 January 14 3/8
February 4 7/8 February 2 1/2 February 4 3/4 February 2 3/4 February 5 5/8 February 13 7/8
March 4 5/16 March 2 1/4 March 4 1/4 March 2 9/16 March 6 7/8 March 14 3/4
April 3 1/4 April 2 April 4 3/8 April 2 7/8 April 6 April 13
May 3 May 2 3/8 May 4 May 2 1/2 May 5 3/8 May 14 3/8
June 2 3/4 June 2 3/8 June 3 1/2 June 2 1/4 June 6 3/8 June 20 11/16
July 2 9/16 July 3 3/8 July 2 11/16 July 2 3/4 July 6 9/16 July 24 1/8
August 2 7/16 August 3 1/4 August 2 3/8 August 3 13/16 August 4 1/16 August 33 3/4
September 3 1/8 September 3 3/4 September 2 3/8 September 4 7/8 September 6 5/8 September 30 1/2
October 2 1/4 October 2 5/8 October 2 1/2 October 6 1/8 October 6 October 29 5/16
November 2 1/8 November 2 3/16 November 2 7/16 November 5 15/16 November 12
December 1 3/4 December 2 1/8 December 2 15/16 December 5 1/2 December 13 9/16
</TABLE>
The closing price on November 22, 1999 was 35.
A-4
<PAGE>
GENENTECH, INC.
Genentech, Inc. uses human genetic information to discover, develop,
manufacture and market human pharmaceuticals. Genentech focuses on the
cardiovascular area and on oncology. Genetech's products are used for, among
other things, the treatment of certain forms of breast cancer, lymphoma, and to
assist with the treatment of cystic fibrosis. Genentech markets biotechnology
products on its own and through licensing agreements. Genentech effected a
2-for-1 stock split on its common stock to shareholders of record on October
29, 1999. The stock began trading on a split-adjusted basis on November 3,
1999. The following table is adjusted to account for this stock split.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- ------- --------- ------- --------- -------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January * January * January * January * January * January *
February * February * February * February * February * February *
March * March * March * March * March * March *
April * April * April * April * April * April *
May * May * May * May * May * May *
June * June * June * June * June * June *
July * July * July * July * July * July 71
August * August * August * August * August * August 82 1/8
September * September * September * September * September * September 73 5/32
October * October * October * October * October * October 72 7/8
November * November * November * November * November *
December * December * December * December * December *
</TABLE>
The closing price on November 22, 1999 was 88 15/16.
GENZYME CORPORATION
Genzyme Corporation develops and markets therapeutic and surgical
products, as well as diagnostic services and products. Genzyme also develops
and markets biological products and devices for the treatment of a genetic
disorder called Gaucher disease, renal diseases, thyroid cancer and other
conditions. Genzyme markets many of its products directly to physicians,
hospitals and treatment centers around the world through its own sales force.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- -------- --------- -------- --------- -------- --------- -------- --------- --------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 14 15/16 January 16 51/64 January 36 5/32 January 26 11/16 January 25 47/64 January 53 39/64
February 13 19/64 February 18 15/32 February 32 7/8 February 24 17/32 February 283 33/64 February 44 17/64
March 12 31/64 March 18 15/32 March 26 13/64 March 21 7/16 March 30 55/64 March 49 5/8
April 13 17/32 April 20 3/8 April 26 51/64 April 22 1/32 April 29 53/64 April 37 9/64
May 13 19/64 May 17 5/8 May 27 3/4 May 22 3/4 May 26 13/32 May 39 29/32
June 12 3/16 June 19 1/16 June 23 15/16 June 26 7/16 June 24 21/32 June 48 1/2
July 13 15/32 July 23 15/32 July 23 45/64 July 26 9/32 July 30 11/32 July 56 9/16
August 15 55/64 August 26 5/8 August 22 3/4 August 27 1/8 August 26 1/32 August 56 7/16
September 15 63/64 September 27 41/64 September 24 19/64 September 28 11/16 September 34 27/32 September 45 1/16
October 15 9/32 October 27 3/4 October 21 59/64 October 26 13/32 October 40 9/16 October 38 1/4
November 13 7/8 November 31 3/32 November 21 11/16 November 25 55/64 November 41 3/8
December 15 1/64 December 29 23/32 December 20 47/64 December 26 49/64 December 48 15/16
</TABLE>
The closing price on November 22, 1999 was 37 1/16.
A-5
<PAGE>
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a biopharmaceutical company that discovers,
develops and commercializes therapeutics for viral diseases. Gilead developed
and markets, in the United States, VISTIDE, which is used for the treatment of
a sight-threatening viral infection in patients with acquired immune deficiency
syndrome (AIDS). Gilead is also developing products to treat diseases caused by
HIV, the hepatitis B virus and the influenza virus.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- -------- --------- ------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 12 3/4 January 13 January 35 3/4 January 32 5/8 January 40 1/2 January 43
February 12 February 14 1/4 February 35 1/2 February 30 1/2 February 35 13/16 February 41 1/4
March 10 3/4 March 13 March 28 3/4 March 22 7/8 March 36 March 45 1/2
April 9 April 15 April 30 1/2 April 22 1/8 April 38 April 46 1/16
May 7 3/4 May 16 1/4 May 34 3/4 May 27 1/8 May 32 3/8 May 43 5/8
June 8 1/2 June 17 5/8 June 25 1/4 June 27 5/8 June 32 1/16 June 52 1/4
July 9 3/8 July 19 July 19 July 28 1/4 July 23 1/2 July 77 1/2
August 10 1/4 August 21 3/4 August 24 1/4 August 32 3/8 August 18 1/4 August 77 15/16
September 11 3/4 September 22 September 28 1/4 September 44 3/8 September 21 5/8 September 64 3/16
October 8 1/2 October 19 1/2 October 23 3/8 October 34 1/8 October 28 3/8 October 63 3/16
November 10 1/4 November 26 1/4 November 25 11/16 November 34 1/2 November 31 1/8
December 9 1/2 December 32 December 25 December 38 1/4 December 41 1/16
</TABLE>
The closing price on November 22, 1999 was 45 7/8.
HUMAN GENOME SCIENCES, INC.
Human Genome Sciences, Inc. researches and develops proprietary
pharmaceutical and diagnostic products based on the discovery and understanding
of the medical utility of genes. Human Genome Sciences researches and develops
recombinant therapeutic proteins, which are proteins that can be produced on a
large scale and used as drugs to treat diseases. Using automated, high-
throughput gene sequencing technology, Human Genome Sciences also generates a
collection of partial human gene sequences in database format.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- ------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 20 January 14 1/8 January 43 1/2 January 46 January 37 7/8 January 33 3/8
February 16 February 12 1/2 February 41 5/8 February 38 February 42 1/2 February 29 7/8
March 16 1/4 March 12 5/8 March 38 1/2 March 32 1/2 March 39 13/16 March 34 11/16
April 17 1/2 April 12 5/8 April 39 3/4 April 31 3/8 April 36 3/8 April 37
May 19 1/2 May 15 May 36 5/8 May 38 3/4 May 36 1/2 May 42 1/4
June 19 1/4 June 16 3/4 June 36 3/4 June 33 1/4 June 35 11/16 June 39 1/2
July 16 July 24 July 30 3/4 July 32 3/8 July 37 1/2 July 52 1/16
August 16 1/2 August 22 August 34 1/8 August 37 1/4 August 24 3/4 August 68 1/16
September 16 1/2 September 21 3/4 September 37 3/4 September 43 1/16 September 30 September 73 3/4
October 17 1/2 October 19 5/8 October 36 1/2 October 41 October 34 5/8 October 87 3/8
November 17 1/2 November 27 November 37 1/4 November 41 November 31 1/4
December 14 3/4 December 38 1/4 December 40 3/4 December 39 3/4 December 35 9/16
</TABLE>
The closing price on November 22, 1999 was 112.
A-6
<PAGE>
ICOS CORPORATION
ICOS Corporation develops proprietary biopharmaceuticals and small
molecule pharmaceuticals for the treatment of inflammatory diseases and other
special medical conditions. ICOS's products address opportunities in the
treatment of chronic and acute diseases that have inflammatory components as
well as certain cardiovascular diseases and cancer. ICOS is developing and
globally commercializing some of its products through a joint venture with Eli
Lily & Company.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 5 7/8 January 4 3/8 January 8 5/8 January 8 January 16 1/16 January 26 3/4
February 5 1/2 February 4 1/2 February 8 1/2 February 8 1/2 February 14 1/16 February 24 1/2
March 5 March 4 3/8 March 9 3/8 March 7 5/16 March 15 1/4 March 33 3/4
April 4 3/8 April 4 5/8 April 8 13/16 April 6 15/16 April 14 3/4 April 39 3/4
May 4 7/8 May 5 1/8 May 8 7/8 May 8 1/16 May 21 1/16 May 43 13/16
June 4 3/8 June 5 3/4 June 8 3/4 June 8 1/4 June 19 1/8 June 40 13/16
July 3 7/8 July 6 3/8 July 6 5/8 July 8 5/8 July 23 1/2 July 37 3/8
August 4 1/2 August 6 7/8 August 7 7/8 August 9 5/8 August 14 7/8 August 31 13/16
September 4 3/4 September 6 7/8 September 8 3/4 September 12 5/8 September 17 3/4 September 29 1/2
October 4 1/4 October 5 3/4 October 7 1/2 October 14 October 18 1/2 October 28 11/16
November 4 1/4 November 7 November 7 5/8 November 13 13/16 November 21 11/16
December 3 11/16 December 7 3/8 December 7 5/8 December 18 5/16 December 29 3/4
</TABLE>
The closing price on November 22, 1999 was 32 3/4.
IDEC PHARMACEUTICALS CORPORATION
IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged
primarily in the research, development and commercialization of targeted
therapies for the treatment of cancer and autoimmune and inflammatory diseases.
IDEC's first commercial product, "Rtuxan", treats certain B-cell non-Hodgkin's
lymphomas, which is a type of cancer of the lymphatic system. IDEC also
develops products for the treatment of certain solid tumor cancers and various
autoimmune diseases.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 6 1/2 January 2 9/16 January 21 1/2 January 23 1/4 January 41 3/4 January 50 1/2
February 5 1/4 February 3 3/4 February 20 1/4 February 24 7/8 February 45 3/8 February 43 5/16
March 3 7/8 March 3 3/4 March 22 1/4 March 23 13/16 March 44 1/4 March 51 3/8
April 3 5/8 April 4 April 28 7/8 April 17 3/4 April 36 April 50 3/4
May 3 3/4 May 4 1/2 May 25 3/4 May 22 1/2 May 31 1/2 May 50 7/16
June 2 7/16 June 5 5/8 June 23 1/8 June 24 1/4 June 23 9/16 June 77 1/16
July 2 3/4 July 6 3/4 July 15 1/2 July 27 1/4 July 23 11/16 July 99 1/8
August 2 3/4 August 6 7/8 August 23 3/8 August 30 3/8 August 18 August 12 1/16
September 2 3/8 September 7 7/8 September 24 September 41 7/8 September 23 3/4 September 94 1/32
October 2 7/8 October 11 7/8 October 21 5/8 October 38 1/8 October 29 7/8 October 116 3/16
November 2 1/2 November 13 1/4 November 24 1/4 November 34 15/16 November 33 5/8
December 2 1/8 December 19 1/2 December 23 3/4 December 34 3/8 December 47
</TABLE>
The closing price on November 22, 1999 was 134 1/2.
A-7
<PAGE>
IMMUNEX CORPORATION
Immunex Corporation is a biopharmaceutical company that discovers,
develops, manufactures and markets therapeutic products. Immunex's products are
used to treat human diseases, including cancer, infectious diseases and
immunological disorders such as rheumatoid arthritis. Immunex focuses on the
discovery and development of molecules with potential applications for the
treatment of asthma, cancer, multiple sclerosis, AIDS and certain inflammatory
diseases.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 4 13/16 January 3 13/16 January 4 3/32 January 5 3/64 January 13 47/64 January 39 1/32
February 3 15/16 February 4 3/16 February 4 February 7 1/16 February 14 25/32 February 35 3/8
March 3 1/2 March 4 5/16 March 4 1/32 March 6 5/8 March 16 27/32 March 41 5/8
April 3 11/32 April 3 April 3 29/32 April 6 31/32 April 17 5/32 April 47 1/4
May 3 7/16 May 3 1/4 May 3 7/8 May 7 27/32 May 15 7/16 May 65 1/16
June 3 3/16 June 3 1/4 June 3 13/32 June 9 1/16 June 16 9/16 June 63 23/32
July 3 1/4 July 3 1/2 July 3 5/32 July 9 9/16 July 17 11/16 July 56 7/16
August 3 13/16 August 3 7/8 August 3 9/32 August 10 15/16 August 12 21/32 August 67 5/16
September 3 7/16 September 3 9/16 September 3 1/4 September 16 13/16 September 13 27/32 September 43 3/8
October 3 3/8 October 3 3/16 October 3 3/8 October 16 October 17 17/64 October 63
November 4 1/16 November 4 9/64 November 3 3/8 November 14 9/32 November 23 1/32
December 3 23/32 December 4 1/8 December 4 7/8 December 13 1/2 December 31 29/64
</TABLE>
The closing price on November 22, 1999 was 72 1/2.
MEDIMMUNE, INC.
MedImmune, Inc. is a biotechnology company that focuses on using advances
in immunology and other biological sciences to develop products that address
medical needs in areas such as infectious diseases, transplantation medicine,
autoimmune diseases and cancer. MedImmune markets three products through its
hospital-based sales force and has five new product candidates in clinical
trial. One of MedImmune's products, Synagis, is used to prevent respiratory
syncytial virus in high-risk pediatric patients. Respiratory syncytial virus is
the leading cause of pneumonia and bronchiolitis in infants and children.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- -------- --------- -------- --------- ---------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 6 7/16 January 3 9/16 January 9 1/8 January 7 15/16 January 22 15/16 January 49 1/2
February 6 1/4 February 3 1/2 February 9 3/8 February 7 1/4 February 25 15/16 February 55
March 5 3/16 March 3 3/16 March 7 7/8 March 6 7/8 March 27 9/16 March 59 3/16
April 4 13/16 April 3 3/4 April 8 1/4 April 6 1/2 April 26 3/8 April 55 1/8
May 4 1/8 May 4 3/8 May 9 5/16 May 7 3/4 May 24 15/16 May 63 5/8
June 4 3/8 June 7 3/16 June 8 1/2 June 9 1/4 June 31 13/16 June 67 3/4
July 2 7/16 July 4 1/2 July 6 7/8 July 11 7/8 July 29 25/64 July 79 7/8
August 2 3/8 August 6 3/16 August 7 August 13 1/4 August 24 1/8 August 103 3/16
September 2 5/16 September 5 9/16 September 7 1/8 September 18 3/8 September 32 3/8 September 99 21/32
October 2 3/16 October 5 7/16 October 7 3/4 October 19 15/16 October 33 5/8 October 112
November 2 3/16 November 6 3/8 November 7 5/8 November 19 1/8 November 33 7/16
December 1 3/4 December 10 December 8 1/2 December 21 7/16 December 49 23/32
</TABLE>
The closing price on November 22, 1999 was 126 3/4.
A-8
<PAGE>
MILLENNIUM PHARMACEUTICALS, INC.
Millennium Pharmaceuticals, Inc. uses genetics, genomics (the study of
genes and their function) and bioinformatics to identify the genes responsible
for common, major diseases and to determine the gene's role in disease
initiation and progression. Some of Millennium's disease targets include:
obesity, type II diabetes, asthma & allergy, cardiovascular diseases, cancer,
central nervous system disorders and osteoporosis.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January * January * January * January 19 3/8 January 18 13/16 January 37 31/32
February * February * February * February 16 3/4 February 20 1/8 February 31 1/16
March * March * March * March 13 5/8 March 18 5/8 March 31 1/4
April * April * April * April 14 3/4 April 19 April 37 3/16
May * May * May 20 1/4 May 17 1/2 May 17 5/8 May 37 7/8
June * June * June 15 1/2 June 16 1/8 June 14 1/8 June 36
July * July * July 15 1/2 July 14 5/8 July 15 July 62 1/2
August * August * August 18 1/4 August 13 1/2 August 11 1/2 August 58 15/16
September * September * September 18 1/4 September 19 1/2 September 17 3/8 September 65
October * October * October 20 3/8 October 19 15/16 October 18 3/8 October 70 1/8
November * November * November 17 3/4 November 20 November 20 3/8
December * December * December 17 3/8 December 19 December 25 7/8
</TABLE>
The closing price on November 22, 1999 was 87 1/4.
PE CORP-PE BIOSYSTEMS GROUP
PE Corp-PE Biosystems Group researches, develops, manufactures, sells and
supports instrument systems, reagents and software for the pharmaceutical,
biotechnology, environmental testing, food, human identification, agriculture
and chemical manufacturing industries. PE Corp-PE Biosystems Group is also
undertaking the sequencing of the human genome along with other model
organisms. Building on the sequence data, it will seek to develop and compile
biological and medical data to create an information portal for the life
science and medical community.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- -------- --------- -------- --------- -------- --------- -------- --------- -------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 19 1/2 January 13 3/4 January 23 5/8 January 34 15/16 January 29 1/2 January 47 17/32
February 18 13/16 February 14 5/16 February 23 1/8 February 35 1/2 February 36 19/32 February 47 3/8
March 16 11/16 March 14 9/16 March 27 1/16 March 32 3/16 March 36 5/32 March 48 17/32
April 14 1/2 April 15 9/16 April 27 7/16 April 36 5/16 April 34 3/16 April 54 1/16
May 14 9/16 May 17 3/8 May 26 1/2 May 38 May 34 1/4 May 55 27/32
June 14 3/4 June 17 11/16 June 24 1/8 June 39 25/32 June 31 3/32 June 57 3/8
July 14 3/16 July 17 July 26 1/8 July 40 13/16 July 29 5/16 July 56 1/16
August 14 15/16 August 17 1/16 August 25 15/16 August 37 August 28 15/16 August 68 13/16
September 15 11/16 September 17 13/16 September 28 15/16 September 36 17/32 September 34 11/32 September 72 1/4
October 14 3/4 October 17 9/16 October 26 13/16 October 31 1/4 October 42 5/32 October 64 7/8
November 13 13/16 November 18 November 30 13/16 November 34 25/32 November 46 5/8
December 12 13/16 December 18 7/8 December 29 7/16 December 35 17/32 December 48 25/32
</TABLE>
The closing price on November 22, 1999 was 81 1/16.
A-9
<PAGE>
QLT PHOTOTHERAPEUTICS INC.
QLT PhotoTherapeutics Inc. develops and commercializes proprietary
pharmaceutical products for use in photodynamic therapy, a biotechnological
field of medicine that utilizes light-activated drugs in the treatment of
disease. QLT's products are derived from naturally-occurring substances in the
human body which are modified to enable them to be activated by light. QLT
currently provides "PHOTOFRIN," a photodynamic therapy drug used in the
treatment of various cancers. QLT is also developing "Visudyne," a
photosensitizer for the treatment of the wet form of age-related macular
degeneration, the leading cause of severe vision loss in people over the age of
50. QLT has ongoing development programs to apply photodynamic therapy for the
treatment of non-melanoma skin cancer and certain autoimmune and cardiovascular
diseases. QLT effected a 2-for-1 stock split of its common shares in the form
of a stock dividend to shareholders of record on October 8, 1999. The stock
began trading on a split-adjusted basis on October 13, 1999. The following
table is adjusted to account for this stock split.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- -------- --------- -------- --------- ------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 3 9/16 January 2 15/16 January 4 1/2 January 11 5/8 January 6 15/16 January 20 5/32
February 3 1/8 February 2 3/4 February 6 February 13 15/32 February 7 3/16 February 19 1/2
March 3 1/8 March 2 1/2 March 6 1/2 March 10 3/8 March 8 11/16 March 20 3/8
April 3 9/16 April 2 11/16 April 10 1/4 April 11 9/16 April 8 11/16 April 22 27/32
May 3 9/16 May 2 45/64 May 10 11/16 May 11 5/16 May 9 3/4 May 21 7/8
June 2 3/4 June 2 11/16 June 9 1/4 June 10 1/2 June 8 3/8 June 27 1/2
July 3 1/4 July 3 1/2 July 7 11/32 July 10 3/16 July 8 July 32
August 3 9/16 August 3 3/16 August 8 3/8 August 9 9/16 August 6 1/4 August 40 15/16
September 3 3/8 September 3 1/2 September 9 7/64 September 8 7/32 September 5 7/8 September 38 7/32
October 3 11/32 October 3 October 8 15/16 October 8 11/16 October 7 47/64 October 42 3/8
November 3 5/16 November 3 13/16 November 9 11/16 November 6 November 7 29/32
December 2 13/16 December 5 1/16 December 10 1/16 December 5 9/16 December 11 3/8
</TABLE>
The closing price on November 22, 1999 was 44 3/4.
SEPRACOR INC.
Sepracor Inc. is a specialty pharmaceutical company that focuses on the
development and commercialization of potentially improved versions of widely-
prescribed drugs. Sepracor's Improved Chemical Entities pharmaceuticals are
being developed as proprietary, single-isomer or active-metabolite versions of
these drugs. Sepracor genetically re-engineers these popular drugs. For
example, it uses biological systems (i.e., enzymes) to purify the mixture of
two isomers common in many drugs into compounds containing a single isomer.
These re-engineered pharmaceuticals are designed to improve patient outcome
through reduced side effects, increased therapeutic efficacy, or improved
dosage forms. Sepracor's portfolio focuses on the allergy/asthma,
urology/gastroenterology and psychiatry/neurology markets.
<TABLE>
<CAPTION>
Closing Closing Closing Closing Closing Closing
1994 Price 1995 Price 1996 Price 1997 Price 1998 Price 1999 Price
- --------- ------- --------- ------- --------- ------- --------- -------- --------- ------- --------- -------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
January 8 1/2 January 6 1/4 January 18 5/8 January 26 1/2 January 35 1/8 January 114 3/4
February 8 5/8 February 7 1/2 February 15 1/2 February 24 1/8 February 40 1/4 February 124 3/4
March 7 March 10 1/8 March 14 5/8 March 23 1/16 March 42 5/8 March 112 1/4
April 5 1/2 April 9 43/64 April 14 April 19 1/2 April 46 1/4 April 84 1/2
May 6 May 12 May 14 5/8 May 24 1/2 May 43 May 63 3/4
June 5 5/8 June 13 1/2 June 15 June 25 13/16 June 41 1/2 June 81 1/4
July 5 3/8 July 14 7/8 July 13 1/2 July 25 1/8 July 54 July 73 1/2
August 4 3/4 August 18 3/4 August 13 1/4 August 22 August 47 5/8 August 74 7/8
September 4 13/14 September 21 5/8 September 14 1/8 September 32 7/8 September 65 3/4 September 75 1/2
October 5 5/16 October 16 7/8 October 16 1/4 October 35 7/8 October 68 5/8 October 83 3/16
November 3 7/8 November 16 November 16 5/8 November 36 7/8 November 83
December 4 1/8 December 18 3/8 December 16 5/8 December 40 1/16 December 88 1/8
</TABLE>
The closing price on November 22, 1999 was 107.
A-10
<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
[LOGO OF BIOTECH HOLDRs](SM)
1,000,000,000 Depositary Receipts
Biotech HOLDRs(SM) Trust
-------------------
P R O S P E C T U S
-------------------
Merrill Lynch & Co.
November 22, 1999
Until December 17, 1999 (25 days after the date of this prospectus), all
dealers effecting transactions in the offered Biotech HOLDRs, whether or not
participating in this distribution, may be required to deliver a prospectus.
This requirement is in addition to the obligations of dealers to deliver a
prospectus when acting as underwriters and with respect to unsold allotments or
subscriptions.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
